MedPath

A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma

Recruiting
Conditions
Pancreas Cancer
Predictive Cancer Model
Registration Number
NCT05997147
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Brief Summary

Importance: Lymphovascular invasion (LVI) is a poor prognosis pathologic feature in pancreatic ductal adenocarcinoma (PDAC) patients. Neoadjuvant therapy may bring survival benefits to these patients.

Objective: To construct a preoperative model which could predict LVI in PDAC patients and further validate it in other cohorts.

Design, Setting, and Participants: Patients from 3 three tertiary hospitals were included in this study. Univariate and multivariate Logistic regression analyses were conducted to define independent prediction factors of LVI. A nomogram was constructed based on the result of multivariate analysis.The predictive value of the model was assessed using receiver operating characteristic (ROC) curves and the maximum Youden index of the ROC curve was defined as the cut-off point. The calibration plot was utilized to assess the concordance of the model. The decision curve analyses (DCA) were applied to estimate the clinical benefit of using this model to predict LVI.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1009
Inclusion Criteria
  • Patients who were pathologically diagnosed as PDAC and received curative surgery.
Exclusion Criteria
  • Patients with distant metastasis; Patients who received neoadjuvant therapy; Patients with a survival time of less than 1 month.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Recurrence-free survival10 years

Time from operation to the detection of recurrence or last follow-up

Secondary Outcome Measures
NameTimeMethod
Overall survival10 years

Time between surgical resection to death or the last follow-up.

Trial Locations

Locations (1)

Tianjin Medical University Cancer Institute and Hospital

🇨🇳

Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath